The Longevity Science Advisory Panel is dedicated to exploring the impact that a range of factors may have on future life expectancy in the UK. This includes the drivers that are enhancing life expectancy for example, medical advances and social change, as well as the inhibitors such as aspects of lifestyle and delays in development of treatments.

The Longevity Science Advisory Panel will regularly be presented with issues and papers on scientific developments for them to review and analyse to determine the implications on future UK life expectancy. The opinion of the panel will then be shared across the insurance industry, as well as with government, and public offices, where appropriate. The aim is that the panel will be a key source for learning and understanding on the implications of scientific developments on UK life expectancy.

Click to access the webpage featuring the latest paper from the Longevity Science Advisory Panel.

Sir Derek Wanless




Sir Derek Wanless,
Chairman, Longevity Science Advisory Panel
"I have been able to bring together a team of people with the knowledge, expertise and complementary skills that aims to provide better informed opinion on UK longevity, for the future benefit and learning of a wide audience. We now have the opportunity to bring together and robustly review the strategic impact that scientific developments will have on life expectancy in the UK. There is a wealth of research in existence and that is being conducted on clinical and medical advances, developments in epidemiology and social change, but the overall consequencies of all these factors on future health and morbidity is currently poorly understood. The spread of expertise across the panel members aims to bring together the variable factors into a coherent view." – Sir Derek Wanless